Metabolic syndrome in Iranian patients with systemic lupus erythematosus and its determinants
The aim of this study was to determine the prevalence of metabolic syndrome (MetS) in Iranian patients with systemic lupus erythematosus (SLE) and its determinants. In a cross-sectional study, 98 patients with SLE and 95 controls were enrolled. Prevalence of MetS was determined based on American Hea...
Gespeichert in:
| Veröffentlicht in: | Clinical rheumatology 2018-06, Vol.37 (6), p.1521-1528 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1528 |
|---|---|
| container_issue | 6 |
| container_start_page | 1521 |
| container_title | Clinical rheumatology |
| container_volume | 37 |
| creator | Fatemi, Alimohammad Ghanbarian, Azadeh Sayedbonakdar, Zahra Kazemi, Mehdi Smiley, Abbas |
| description | The aim of this study was to determine the prevalence of metabolic syndrome (MetS) in Iranian patients with systemic lupus erythematosus (SLE) and its determinants. In a cross-sectional study, 98 patients with SLE and 95 controls were enrolled. Prevalence of MetS was determined based on American Heart Association and National Heart, Lung, and Blood Institute (AHA/NHLBI) and 2009 harmonizing criteria. In addition, demographic features and lupus characteristics such as disease duration, pharmacological treatment, laboratory data, SLE disease activity index (SLEDAI), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage index (SDI) were recorded. The predictors of MetS were obtained by backward stepwise regression analysis. Using AHA/NHLBI, MetS was observed in 35 (35.7%) patients and 28 (29.8%) controls (
P
= 0.4). Using harmonizing criteria, MetS was observed in 37 (37.7%) patients and 33 (35.1%) controls (
P
= 0.7). There was no difference in frequency distribution of MetS components between the patients and the controls. In multivariate regression analysis, low C3, blood urea nitrogen (BUN), and body mass index were independent determinants of MetS in lupus patients. BUN, low C3, and body mass index were the major determinants of MetS in lupus patients. |
| doi_str_mv | 10.1007/s10067-017-3970-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1989548265</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1989548265</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-7b0b215e22e216736818e1bd15206daa24a53698424446e7f247fa41a9cea5483</originalsourceid><addsrcrecordid>eNp1kE1LAzEQhoMotlZ_gBdZ8OJlNclm83GU4keh4kWPErK7U5uym61JFum_N6VVRPCSIZln3gkPQucEXxOMxU1IJxc5JiIvlMB5eYDGhBUsV4qpQzTGIj0WRMkROglhhTGmUpFjNKKqwCXnaozeniCaqm9tnYWNa3zfQWZdNvPGWeOytYkWXAzZp43LRIQIXULbYT2EDPwmLqEzsQ_pZlyT2UQ2EMF31pk0doqOFqYNcLavE_R6f_cyfcznzw-z6e08rwtBYy4qXFFSAqVACRcFl0QCqRpSUswbYygzZcGVZJQxxkEsKBMLw4hRNZiSyWKCrna5a99_DBCi7myooW2Ng34IOilQiaO8TOjlH3TVD96l320pJiWWWCWK7Kja9yF4WOi1t53xG02w3rrXO_c6uddb93qbfLFPHqoOmp-Jb9kJoDsgpJZ7B_9r9b-pX_Bmjt0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1984880809</pqid></control><display><type>article</type><title>Metabolic syndrome in Iranian patients with systemic lupus erythematosus and its determinants</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Fatemi, Alimohammad ; Ghanbarian, Azadeh ; Sayedbonakdar, Zahra ; Kazemi, Mehdi ; Smiley, Abbas</creator><creatorcontrib>Fatemi, Alimohammad ; Ghanbarian, Azadeh ; Sayedbonakdar, Zahra ; Kazemi, Mehdi ; Smiley, Abbas</creatorcontrib><description>The aim of this study was to determine the prevalence of metabolic syndrome (MetS) in Iranian patients with systemic lupus erythematosus (SLE) and its determinants. In a cross-sectional study, 98 patients with SLE and 95 controls were enrolled. Prevalence of MetS was determined based on American Heart Association and National Heart, Lung, and Blood Institute (AHA/NHLBI) and 2009 harmonizing criteria. In addition, demographic features and lupus characteristics such as disease duration, pharmacological treatment, laboratory data, SLE disease activity index (SLEDAI), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage index (SDI) were recorded. The predictors of MetS were obtained by backward stepwise regression analysis. Using AHA/NHLBI, MetS was observed in 35 (35.7%) patients and 28 (29.8%) controls (
P
= 0.4). Using harmonizing criteria, MetS was observed in 37 (37.7%) patients and 33 (35.1%) controls (
P
= 0.7). There was no difference in frequency distribution of MetS components between the patients and the controls. In multivariate regression analysis, low C3, blood urea nitrogen (BUN), and body mass index were independent determinants of MetS in lupus patients. BUN, low C3, and body mass index were the major determinants of MetS in lupus patients.</description><identifier>ISSN: 0770-3198</identifier><identifier>EISSN: 1434-9949</identifier><identifier>DOI: 10.1007/s10067-017-3970-5</identifier><identifier>PMID: 29305669</identifier><language>eng</language><publisher>London: Springer London</publisher><subject>Adult ; Body mass index ; Case-Control Studies ; Cross-Sectional Studies ; Drug therapy ; Female ; Health risk assessment ; Humans ; Iran - epidemiology ; Lupus ; Lupus Erythematosus, Systemic - epidemiology ; Male ; Medicine ; Medicine & Public Health ; Metabolic syndrome ; Metabolic Syndrome - epidemiology ; Middle Aged ; Original Article ; Prevalence ; Regression analysis ; Rheumatology ; Systemic lupus erythematosus ; Urea ; Young Adult</subject><ispartof>Clinical rheumatology, 2018-06, Vol.37 (6), p.1521-1528</ispartof><rights>International League of Associations for Rheumatology (ILAR) 2018</rights><rights>Clinical Rheumatology is a copyright of Springer, (2018). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-7b0b215e22e216736818e1bd15206daa24a53698424446e7f247fa41a9cea5483</citedby><cites>FETCH-LOGICAL-c372t-7b0b215e22e216736818e1bd15206daa24a53698424446e7f247fa41a9cea5483</cites><orcidid>0000-0003-3793-7449</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10067-017-3970-5$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10067-017-3970-5$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51297</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29305669$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fatemi, Alimohammad</creatorcontrib><creatorcontrib>Ghanbarian, Azadeh</creatorcontrib><creatorcontrib>Sayedbonakdar, Zahra</creatorcontrib><creatorcontrib>Kazemi, Mehdi</creatorcontrib><creatorcontrib>Smiley, Abbas</creatorcontrib><title>Metabolic syndrome in Iranian patients with systemic lupus erythematosus and its determinants</title><title>Clinical rheumatology</title><addtitle>Clin Rheumatol</addtitle><addtitle>Clin Rheumatol</addtitle><description>The aim of this study was to determine the prevalence of metabolic syndrome (MetS) in Iranian patients with systemic lupus erythematosus (SLE) and its determinants. In a cross-sectional study, 98 patients with SLE and 95 controls were enrolled. Prevalence of MetS was determined based on American Heart Association and National Heart, Lung, and Blood Institute (AHA/NHLBI) and 2009 harmonizing criteria. In addition, demographic features and lupus characteristics such as disease duration, pharmacological treatment, laboratory data, SLE disease activity index (SLEDAI), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage index (SDI) were recorded. The predictors of MetS were obtained by backward stepwise regression analysis. Using AHA/NHLBI, MetS was observed in 35 (35.7%) patients and 28 (29.8%) controls (
P
= 0.4). Using harmonizing criteria, MetS was observed in 37 (37.7%) patients and 33 (35.1%) controls (
P
= 0.7). There was no difference in frequency distribution of MetS components between the patients and the controls. In multivariate regression analysis, low C3, blood urea nitrogen (BUN), and body mass index were independent determinants of MetS in lupus patients. BUN, low C3, and body mass index were the major determinants of MetS in lupus patients.</description><subject>Adult</subject><subject>Body mass index</subject><subject>Case-Control Studies</subject><subject>Cross-Sectional Studies</subject><subject>Drug therapy</subject><subject>Female</subject><subject>Health risk assessment</subject><subject>Humans</subject><subject>Iran - epidemiology</subject><subject>Lupus</subject><subject>Lupus Erythematosus, Systemic - epidemiology</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metabolic syndrome</subject><subject>Metabolic Syndrome - epidemiology</subject><subject>Middle Aged</subject><subject>Original Article</subject><subject>Prevalence</subject><subject>Regression analysis</subject><subject>Rheumatology</subject><subject>Systemic lupus erythematosus</subject><subject>Urea</subject><subject>Young Adult</subject><issn>0770-3198</issn><issn>1434-9949</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kE1LAzEQhoMotlZ_gBdZ8OJlNclm83GU4keh4kWPErK7U5uym61JFum_N6VVRPCSIZln3gkPQucEXxOMxU1IJxc5JiIvlMB5eYDGhBUsV4qpQzTGIj0WRMkROglhhTGmUpFjNKKqwCXnaozeniCaqm9tnYWNa3zfQWZdNvPGWeOytYkWXAzZp43LRIQIXULbYT2EDPwmLqEzsQ_pZlyT2UQ2EMF31pk0doqOFqYNcLavE_R6f_cyfcznzw-z6e08rwtBYy4qXFFSAqVACRcFl0QCqRpSUswbYygzZcGVZJQxxkEsKBMLw4hRNZiSyWKCrna5a99_DBCi7myooW2Ng34IOilQiaO8TOjlH3TVD96l320pJiWWWCWK7Kja9yF4WOi1t53xG02w3rrXO_c6uddb93qbfLFPHqoOmp-Jb9kJoDsgpJZ7B_9r9b-pX_Bmjt0</recordid><startdate>20180601</startdate><enddate>20180601</enddate><creator>Fatemi, Alimohammad</creator><creator>Ghanbarian, Azadeh</creator><creator>Sayedbonakdar, Zahra</creator><creator>Kazemi, Mehdi</creator><creator>Smiley, Abbas</creator><general>Springer London</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3793-7449</orcidid></search><sort><creationdate>20180601</creationdate><title>Metabolic syndrome in Iranian patients with systemic lupus erythematosus and its determinants</title><author>Fatemi, Alimohammad ; Ghanbarian, Azadeh ; Sayedbonakdar, Zahra ; Kazemi, Mehdi ; Smiley, Abbas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-7b0b215e22e216736818e1bd15206daa24a53698424446e7f247fa41a9cea5483</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adult</topic><topic>Body mass index</topic><topic>Case-Control Studies</topic><topic>Cross-Sectional Studies</topic><topic>Drug therapy</topic><topic>Female</topic><topic>Health risk assessment</topic><topic>Humans</topic><topic>Iran - epidemiology</topic><topic>Lupus</topic><topic>Lupus Erythematosus, Systemic - epidemiology</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metabolic syndrome</topic><topic>Metabolic Syndrome - epidemiology</topic><topic>Middle Aged</topic><topic>Original Article</topic><topic>Prevalence</topic><topic>Regression analysis</topic><topic>Rheumatology</topic><topic>Systemic lupus erythematosus</topic><topic>Urea</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fatemi, Alimohammad</creatorcontrib><creatorcontrib>Ghanbarian, Azadeh</creatorcontrib><creatorcontrib>Sayedbonakdar, Zahra</creatorcontrib><creatorcontrib>Kazemi, Mehdi</creatorcontrib><creatorcontrib>Smiley, Abbas</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fatemi, Alimohammad</au><au>Ghanbarian, Azadeh</au><au>Sayedbonakdar, Zahra</au><au>Kazemi, Mehdi</au><au>Smiley, Abbas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Metabolic syndrome in Iranian patients with systemic lupus erythematosus and its determinants</atitle><jtitle>Clinical rheumatology</jtitle><stitle>Clin Rheumatol</stitle><addtitle>Clin Rheumatol</addtitle><date>2018-06-01</date><risdate>2018</risdate><volume>37</volume><issue>6</issue><spage>1521</spage><epage>1528</epage><pages>1521-1528</pages><issn>0770-3198</issn><eissn>1434-9949</eissn><abstract>The aim of this study was to determine the prevalence of metabolic syndrome (MetS) in Iranian patients with systemic lupus erythematosus (SLE) and its determinants. In a cross-sectional study, 98 patients with SLE and 95 controls were enrolled. Prevalence of MetS was determined based on American Heart Association and National Heart, Lung, and Blood Institute (AHA/NHLBI) and 2009 harmonizing criteria. In addition, demographic features and lupus characteristics such as disease duration, pharmacological treatment, laboratory data, SLE disease activity index (SLEDAI), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage index (SDI) were recorded. The predictors of MetS were obtained by backward stepwise regression analysis. Using AHA/NHLBI, MetS was observed in 35 (35.7%) patients and 28 (29.8%) controls (
P
= 0.4). Using harmonizing criteria, MetS was observed in 37 (37.7%) patients and 33 (35.1%) controls (
P
= 0.7). There was no difference in frequency distribution of MetS components between the patients and the controls. In multivariate regression analysis, low C3, blood urea nitrogen (BUN), and body mass index were independent determinants of MetS in lupus patients. BUN, low C3, and body mass index were the major determinants of MetS in lupus patients.</abstract><cop>London</cop><pub>Springer London</pub><pmid>29305669</pmid><doi>10.1007/s10067-017-3970-5</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0003-3793-7449</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0770-3198 |
| ispartof | Clinical rheumatology, 2018-06, Vol.37 (6), p.1521-1528 |
| issn | 0770-3198 1434-9949 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1989548265 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Body mass index Case-Control Studies Cross-Sectional Studies Drug therapy Female Health risk assessment Humans Iran - epidemiology Lupus Lupus Erythematosus, Systemic - epidemiology Male Medicine Medicine & Public Health Metabolic syndrome Metabolic Syndrome - epidemiology Middle Aged Original Article Prevalence Regression analysis Rheumatology Systemic lupus erythematosus Urea Young Adult |
| title | Metabolic syndrome in Iranian patients with systemic lupus erythematosus and its determinants |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T06%3A06%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Metabolic%20syndrome%20in%20Iranian%20patients%20with%20systemic%20lupus%20erythematosus%20and%20its%20determinants&rft.jtitle=Clinical%20rheumatology&rft.au=Fatemi,%20Alimohammad&rft.date=2018-06-01&rft.volume=37&rft.issue=6&rft.spage=1521&rft.epage=1528&rft.pages=1521-1528&rft.issn=0770-3198&rft.eissn=1434-9949&rft_id=info:doi/10.1007/s10067-017-3970-5&rft_dat=%3Cproquest_cross%3E1989548265%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1984880809&rft_id=info:pmid/29305669&rfr_iscdi=true |